Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ansel McFaddin

Internal Medicine Sumter, SC Medical Doctor

NPI 1518903111 CMS profile 295989

115 N Sumter St, Suite 115, Sumter, SC 29150

Open in the dashboard

General payments

$1,211

76 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ansel McFaddin of Sumter, SC is reported in the CMS Open Payments database as having received $1,211 across 76 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $74 4
2024 General $36 2
2023 General $282 16
2022 General $238 16
2021 General $355 23
2020 General $139 9
2019 General $87 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ansel McFaddin
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ansel McFaddin were reported at $74. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ansel McFaddin Internal Medicine median Middle half National median
2019 $87 $159 $48–$570 $163
2020 $139 $119 $33–$402 $114
2021 $355 $135 $37–$521 $132
2022 $238 $141 $42–$496 $149
2023 $282 $149 $45–$519 $160
2024 $36 $154 $47–$537 $164
2025 $74 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $355 22 payments
  2. AbbVie, Inc. $171 11 payments
  3. Abbott Laboratories $136 7 payments
  4. Janssen Pharmaceuticals, Inc $109 7 payments
  5. E.R. Squibb & Sons, L.L.C. $74 5 payments
  6. Pfizer Inc. $72 5 payments
  7. AstraZeneca Pharmaceuticals LP $68 5 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $52 3 payments
  9. GlaxoSmithKline, LLC. $37 3 payments
  10. Dexcom, Inc. $29 2 payments
  11. Other $108 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,211 76 payments
Products named General payments · program years 2019–2025
  1. RYBELSUS $259 17 payments
  2. Ozempic $229 15 payments
  3. FreeStyle Libre 3 $119 6 payments
  4. XARELTO $109 7 payments
  5. VRAYLAR $81 5 payments
  6. Saxenda $80 4 payments
  7. ELIQUIS $74 5 payments
  8. UBRELVY $62 4 payments
  9. TRINTELLIX $52 3 payments
  10. Wegovy $42 2 payments
  11. Other $568 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 53 drugs

Part D claims

1,569

Median for Internal Medicine: 777

Drug cost

$92,348

Median for Internal Medicine: $73,373

Branded share of claims

18.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 47 $32,681
Jardiance Empagliflozin Brand 17 $13,556
Ozempic Semaglutide Brand 12 $10,789
Entresto Sacubitril/Valsartan Brand 12 $9,961
Rosuvastatin Calcium Generic 85 $2,810
Premarin Estrogens, Conjugated Brand 11 $2,627
Olmesartan Medoxomil Generic 27 $1,458
Esomeprazole Magnesium Generic 17 $1,377
Metoprolol Succinate Generic 53 $1,057
Atorvastatin Calcium Generic 88 $906

The 10 drugs with the highest cost, of 53 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

76 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record